Hypertension and incident cardiovascular events following ibrutinib initiation

Tyler Dickerson, Tracy Wiczer, Allyson Waller, +10

Blood

Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib

Tracy Wiczer, Lauren Levine, Jessica Brumbaugh, +20

Blood Advances

Heart FailurePharmacotherapyAcute Myocardial InfarctionThrombosisCumulative Incidence +17

Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity

Tracy Wiczer, Emily Dotson, Amy Tuten, +2

Journal of Oncology Pharmacy Practice

Ventricular arrhythmias and sudden death events following acalabrutinib initiation

Seema A. Bhat, John Alan Gambril, Leylah Azali, +14

Blood

Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation

Sunnia T. Chen, Leylah Azali, Lindsay Rosen, +15

Journal of Hematology & Oncology

Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center

Kerry A. Rogers, Luay Mousa, Qiuhong Zhao, +12

Blood

Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated Cardiotoxicity

Benjamin Buck, Aaron Chum, Mitkumar Patel, +23

JAMA Oncology

Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists

Kristin L Koenig, Ying Huang, Emily Dotson, +13

Blood Advances

A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer – A real world experience

Megan Phelps, Tracy Wiczer, H. Paige Erdeljac, +4

Journal of Oncology Pharmacy Practice

Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation

John Alan Gambril, Sanam Ghazi, Stephen Sansoterra, +11

Leukemia